Melanoma trials recruiting in Washington

All Melanoma trials nationally

Cities in Washington

Recruiting trials in Washington

• A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
  NCT06961006 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
  NCT06150664 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Spokane
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
  NCT05914116 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Spokane
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
  NCT06581406 · Phase: Phase 2, Phase 3 · Ages: No age limits stated · Sex: All (male and female) · Washington: Seattle
• A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
  NCT06246916 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Edmonds, Issaquah, Kennewick, Seattle
• A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
  NCT07492680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
  NCT06172478 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• A Study of IBI363 in Subjects with Advanced Solid Malignancies
  NCT06281678 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• A Study of NX-1607 in Adults With Advanced Malignancies
  NCT05107674 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
  NCT05592626 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
  NCT04511013 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Aberdeen, Bellingham, Centralia, Edmonds
• A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
  NCT06330064 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Wenatchee
• A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
  NCT05538130 · Phase: Phase 1 · Ages: 16 Years and older · Sex: All (male and female) · Washington: Seattle
• ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
  NCT03686124 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
  NCT06418204 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Washington: Bellevue, Edmonds, Issaquah, Kennewick
• BostonGene and Exigent Genomic INsight Study
  NCT06272864 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Washington: Puyallup
• Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
  NCT05334069 · Phase: Not specified · Ages: 40 Years to 75 Years · Sex: All (male and female) · Washington: Aberdeen, Bellingham, Burien, Centralia
• DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
  NCT06953089 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Puyallup, Spokane
• High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
  NCT06298734 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
  NCT06112314 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
  NCT05098210 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• Project: Every Child for Younger Patients With Cancer
  NCT02402244 · Phase: Not specified · Ages: Up to 25 Years · Sex: All (male and female) · Washington: Seattle, Spokane, Tacoma
• Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
  NCT06814496 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Washington: Seattle
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
  NCT06743126 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Washington: Seattle
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Tacoma
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  NCT05379985 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
  NCT05727904 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Washington: Edmonds
• TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
  NCT04485013 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Tacoma, Vancouver
• Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
  NCT05549297 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
  NCT04851119 · Phase: Phase 1, Phase 2 · Ages: 12 Months to 30 Years · Sex: All (male and female) · Washington: Seattle
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
  NCT06500455 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Renton, Vancouver